Research institute
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
Scientists from the University of Pennsylvania developed a new approach to address fibrosis, a leading cause of heart disease.
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
As the Omicron strain sweeps the world, researchers rush to determine how effective vaccines are at creating immunity against the variant. For that and more, continue reading.
This California biotech just bagged another partner for its endeavor to cure autoimmune disease with cell therapy.
New Year is coming, and COVID-19 is still at play. For more COVID-19 studies, vaccines, and treatments, here are the latest updates.
Studies found that AstraZeneca’s EVUSHELD was still effective against the Omicron variant. EVUSHELD is a long-acting antibody combination made up of tixagevimab and cilgavimab.
New real-world studies from Scotland and England shows that Omicron does not lead to as much hospitalization as Delta. This is consistent with the latest reports from South Africa that say Omicron causes milder disease.
In the last week, Omicron is credited for 73% of new COVID-19 infections and is accounted for 12.6% of positive cases, making it the most rapidly spreading variant the country has seen yet.
Here’s a look at 10 of the more compelling research stories of the year.
PRESS RELEASES